Stock Market Reviews

SUPN (Supernus Pharmaceuticals, Inc.) News

Get the latest news, insights, and market updates on SUPN (Supernus Pharmaceuticals, Inc.). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• 1 Healthcare Stock Worth Your Attention and 2 Facing Headwinds
  Personal health and wellness is one of the many secular tailwinds for healthcare companies. Shareholders who bet on the industry have been rewarded lately as healthcare stocks have returned 14.4% over the past six months, topping the S&P 500 by 4 percentage points.
  Nov 24, 2025 - $SUPN
• Assessing Supernus Pharmaceuticals After FDA Pipeline News and 24% Jump in 2025
  Wondering whether Supernus Pharmaceuticals is still a smart buy after its latest run, or if the market has already priced in the best news? You are not alone; valuation is at the heart of most investment decisions. The stock recently gained 0.5% over the last week, bouncing back from a tough 14.2% drop in the past month. Yet it is still up a strong 24.4% so far this year and 25.5% over the last twelve months. Supernus Pharmaceuticals has attracted investor attention...
  Nov 24, 2025 - $SUPN
• Branded Pharmaceuticals Stocks Q3 Results: Benchmarking Supernus Pharmaceuticals (NASDAQ:SUPN)
  Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Supernus Pharmaceuticals (NASDAQ:SUPN) and the best and worst performers in the branded pharmaceuticals industry.
  Nov 21, 2025 - $SUPN
• Supernus Pharmaceuticals to Participate in the Piper Sandler 37th Annual Healthcare Conference
  ROCKVILLE, Md., Nov. 21, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack A. Khattar, President and CEO of Supernus Pharmaceuticals, will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Tuesday, December 2, 2025, at 4:00 p.m. ET at the Lotte New York Palace in New York C
  Nov 21, 2025 - $SUPN
• 3 Russell 2000 Stocks Walking a Fine Line
  The Russell 2000 (^RUT) is home to many small-cap stocks, offering investors the chance to uncover hidden gems before the broader market catches on. However, these companies often come with higher volatility and risk, as their smaller size makes them more vulnerable to economic downturns.
  Nov 14, 2025 - $SUPN
• Supernus to Participate in the 2025 Jefferies Global Healthcare Conference in London
  ROCKVILLE, Md., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack A. Khattar, President and CEO of Supernus Pharmaceuticals, will participate in a fireside chat at the 2025 Jefferies Global Healthcare Conference in London on Monday, November 17, 2025, at 9:30 a.m. EST (2:30 p.m. GMT). Investors interest
  Nov 12, 2025 - $SUPN
• 5 Must-Read Analyst Questions From Supernus Pharmaceuticals’s Q3 Earnings Call
  Supernus Pharmaceuticals reported Q3 results that were above Wall Street’s revenue and profit expectations, but the market reacted negatively, reflecting concerns over execution challenges and forward guidance. Management attributed quarterly growth to robust demand for Qelbree and GOCOVRI, as well as initial contributions from Onapgo and collaboration revenue from Zurzuvae. CEO Jack Khattar acknowledged that supply constraints for Onapgo limited the company’s ability to fully meet patient deman
  Nov 11, 2025 - $SUPN
• Supernus Pharmaceuticals (SUPN) Profit Margin Soars, Challenging Cautious Earnings Narratives
  Supernus Pharmaceuticals (SUPN) posted a net profit margin of 9.7%, a major jump from 0.8% last year, signaling a powerful turnaround in profitability. Earnings soared 1131.1% over the past year, a significant reversal from the company’s five-year trend of a 27% annual decline. Analysts are now projecting annual revenue growth of 14.6% and profit growth of 54%, both well ahead of US market norms. The stock trades below average price targets, setting up an intriguing story for investors to...
  Nov 6, 2025 - $SUPN
• Supernus Pharmaceuticals (SUPN) is Benefiting from Its Strength in Financial Position
  Third Avenue Management, an investment management company based in New York City, released its “Third Avenue Small-Cap Value Fund” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. During the quarter, the fund returned 7.18% compared to 8.97% for the MSCI USA Small-Cap Value Index (the “Index”) and 12.60% return for […]
  Nov 6, 2025 - $SUPN
• SUPN Q3 Deep Dive: Growth Drivers Offset By Supply Constraints and Integration Costs
  Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) announced better-than-expected revenue in Q3 CY2025, with sales up 9.3% year on year to $192.1 million. On the other hand, the company’s full-year revenue guidance of $695 million at the midpoint came in 1.1% below analysts’ estimates. Its GAAP loss of $0.80 per share was 13.7% above analysts’ consensus estimates.
  Nov 5, 2025 - $SUPN